>>Signaling Pathways>> Neuroscience>> Dopamine Receptor>>D-Tetrahydropalmatine

D-Tetrahydropalmatine (Synonyms: (+)-Corydalis B, (+)-Tetrahydropalmatine, (R)-Tetrahydropalmatine, D-THP)

Catalog No.GC38228

D-테트라히드로팔마틴은 주로 현호색속 속에 속하는 이소퀴놀린 알칼로이드입니다.

Products are for research use only. Not for human use. We do not sell to patients.

D-Tetrahydropalmatine Chemical Structure

Cas No.: 3520-14-7

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$92.00
재고 있음
1mg
US$32.00
재고 있음
5mg
US$83.00
재고 있음
10mg
US$141.00
재고 있음
20mg
US$240.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com


고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

D-Tetrahydropalmatine is an isoquinoline alkaloid, mainly in the genus Corydalis[1]. D-Tetrahydropalmatine is a Dopamine (DA) receptor antagonist with preferential affinity toward the D1 receptors[2]. D-Tetrahydropalmatine is a potent organic cation transporter 1 (OCT1) inhibitor[3].

[1]. Ma ZJ, et al. [Effects of different types and standard of processing vinegaron inherent constituents in rhizoma of Corydalis yanhusuo]. Zhongguo Zhong Yao Za Zhi. 2006 Mar;31(6):465-7. [2]. Xu SX, et al. Effects of tetrahydroprotoberberines on dopamine receptor subtypes in brain. Zhongguo Yao Li Xue Bao. 1989 Mar;10(2):104-10. [3]. Tu M, et al. Organic cation transporter 1 mediates the uptake of monocrotaline and plays an important rolein its hepatotoxicity. Toxicology. 2013 Sep 15;311(3):225-30.

리뷰

Review for D-Tetrahydropalmatine

Average Rating: 5 ★★★★★ (Based on Reviews and 21 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for D-Tetrahydropalmatine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.